StonvexLoading…
StonvexStonvexStonvexCore line items from AKAM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $4.21B | $3.99B | $3.81B | $3.62B |
Operating Income | $566.94M | $533.41M | $637.34M | $676.27M |
Net Income | $452.03M | $504.92M | $547.63M | $523.67M |
EPS (Diluted) | $3.07 | $3.27 | $3.52 | $3.26 |
Total Assets | $11.48B | $10.37B | $9.90B | $8.30B |
Total Liabilities | $6.50B | $5.49B | $5.30B | $3.94B |
Cash & Equivalents | $930.23M | $517.71M | $489.47M | $542.34M |
Free Cash Flow OCF − CapEx | $1.01B | $1.13B | $890.53M | $1.03B |
Shares Outstanding | 144.71M | 150.03M | 151.23M | 156.49M |